Our take
Toumai is a four-arm laparoscopic robot with force feedback, approved in China in 2022 and in the EU in 2024. It has passed 300 global commercial orders and is installed in more than 60 countries, and it has approval for telesurgery in nearly 20 countries and regions.2,4,7
It suits hospitals that want a multi-port soft-tissue robot at a lower price than da Vinci, or that want remote surgery. MedBot does not publish prices; Chinese public tenders in 2025 averaged about 12.77 million yuan per Toumai system against 18.17 million for da Vinci.10
Scores by criterion
Pricing transparency, 4.5: MedBot lists no prices, but its 11 public tender awards in China in 2025 are published, at an average of about 12.77 million yuan per system.1,10
Product maturity, 8.0: MedBot began work on Toumai in 2014. Toumai was approved in China in 2022 as the first domestic four-arm laparoscopic robot, received EU CE certification in 2024, and received CE MDR certification for telesurgery in 2026.2,1
Deployment evidence, 8.0: Toumai passed 300 global commercial orders in June 2026 and is installed at hospitals including Ruijin Hospital, West China Hospital, Cleveland Clinic Abu Dhabi, and Gemelli in Rome, where a randomized prostatectomy study found results comparable to an established robot.4,7
Company durability, 6.5: Revenue more than doubled to 551.1 million yuan in 2025, and the loss narrowed to 254.1 million yuan. MedBot expects its first half-year profit for the first six months of 2026, and it is a listed subsidiary of MicroPort Scientific.8,5,7
Ease of integration, 7.0: Toumai supports telesurgery, including over 5G and satellite links, and MedBot also makes the DFVision 3D laparoscope used with its robots.4,1,2
Each criterion is defined on our methodology page.
Who uses MedBot and what it's for
The buyer is a hospital, in China or abroad, that wants a multi-port soft-tissue surgical robot for urology, general, gynecological, or thoracic surgery, or a telesurgery program.2,4
Buyers should compare it with Intuitive da Vinci, Edge Medical, CMR Surgical, SS Innovations, and Distalmotion.
Toumai, SkyWalker, and other robots
MedBot says it is the only surgical robot company with businesses in five segments: laparoscopic, orthopedic, vascular interventional, natural orifice, and percutaneous robots.7
SkyWalker, its hip and knee replacement robot, is approved in China and has CE certification in Europe. MedBot also makes the R-One vascular intervention robot.2,1
Orders, installs, and studies
By the end of 2025 Toumai had about 220 global commercial orders and more than 140 installs, with more than 100 new overseas orders and 80 overseas installs in 2025 alone.8
Brazil chose Toumai as the technology platform for a national telesurgery network for its public health system in 2026.6
Pricing
MedBot does not publish prices. In 2025 Chinese public tenders, MedBot won 11 laparoscopic robot contracts worth 140 million yuan, an average of about 12.77 million yuan, or about 1.77 million dollars, per system.10
Company, leadership, and revenue
MedBot started in 2014 as an internal project of MicroPort, became a company in 2015, and listed on the Hong Kong main board in 2021.2,9
Revenue was 257.2 million yuan in 2024 and 551.1 million yuan in 2025, with overseas sales of 400.2 million yuan, 73 percent of the total, and 464 employees.8
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where MedBot wins or loses |
|---|---|---|---|---|
| MicroPort MedBot | Toumai four-arm laparoscopic robot with telesurgery1 | Not published; about 12.77 million yuan average tender in China, 202510 | 300+ orders; installed in 60+ countries4 | Toumai plus orthopedic and vascular robots; tender pricing; listed, still loss-making in 2025 |
| Intuitive (da Vinci) | da Vinci multi-port and single-port surgical systems11 | Sales plus leases, many with usage-based payments11 | About 12,094 systems installed at September 30, 202611 | Intuitive wins on the largest installed base. MedBot wins on telesurgery approvals and a lower tender price than da Vinci. |
| Edge Medical | MP1000 multi-port and SP1000 single-port robots12 | About RMB14.53M average tender price in China10 | 100 robots installed or delivered, 54 overseas13 | Edge wins on more Chinese tender wins in 2025. MedBot wins on telesurgery approvals and a lower tender price than da Vinci. |
| CMR Surgical (Versius) | Versius Plus modular surgical robot14 | Not published; Stryker to act as US sales agent20 | 45,000 cases worldwide; no dedicated OR required14 | CMR wins on a modular robot that needs no dedicated room. MedBot wins on telesurgery approvals and a lower tender price than da Vinci. |
| SS Innovations | SSi Mantra modular surgical robot15 | Less than a third of a da Vinci's price in a 2022 report16 | 224 systems in twelve countries by June 30, 2026; not yet FDA cleared17,18 | SS Innovations wins on a low price in India. MedBot wins on telesurgery approvals and a lower tender price than da Vinci. |
| Distalmotion (DEXTER) | DEXTER soft-tissue surgical robot with a small, mobile footprint21 | Not published22 | More than 3,000 cumulative procedures in Europe and the US; focus on ASCs23 | Distalmotion wins on a small robot for outpatient centers. MedBot wins on telesurgery approvals and a lower tender price than da Vinci. |
Limits
No published list prices.1
Still lost money in 2025.8
Toumai won fewer Chinese tenders in 2025 than in 2024.10
What customers say
Where it helps
A lower-priced multi-port robot with telesurgery approvals.10,4
Where it falls short
Prices only through tenders and sales.1
Leadership
MedBot does not publish leadership photos. Dr. Chao He is executive director and president, and Dr. Zhaohua Chang sits on the board as a non-executive director.3,4
Sources
- MicroPort MedBot, homepage, accessed November 10, 2026
- MicroPort MedBot, About MedBot and history, accessed November 10, 2026
- MicroPort MedBot, Corporate governance: board of directors, accessed November 10, 2026
- MicroPort MedBot, Toumai surgical robotic system surpasses 300 global commercial orders (June 17, 2026), accessed November 10, 2026
- MicroPort MedBot, first-ever half-year profitability, expected net profit of RMB 28-40 million (July 23, 2026), accessed November 10, 2026
- MicroPort MedBot, Brazil launches national telesurgery network with Toumai (May 15, 2026), accessed November 10, 2026
- MicroPort MedBot, two BMC Surgery studies on the Toumai system (April 30, 2026), accessed November 10, 2026
- MEKAWIRE, MicroPort MedBot 2025 revenue doubles to RMB 551 million (March 26, 2026), accessed November 10, 2026
- National Business Daily, MicroPort MedBot 2025 results call (April 7, 2026), accessed November 10, 2026
- MedChina, 2025 China laparoscopic surgical robot tender report, accessed November 10, 2026
- Intuitive Surgical, Form 10-Q for the quarter ended September 30, 2026, accessed November 1, 2026
- Edge Medical, Homepage, accessed November 9, 2026
- VCBeat, China-made surgical robots, accessed November 9, 2026
- CMR Surgical, Home page, accessed November 1, 2026
- SS Innovations, Investor overview, accessed November 1, 2026
- Business Standard, SSI Mantra costs one-third of global price, September 15, 2022, accessed November 1, 2026
- SS Innovations, Second quarter 2026 financial results, August 13, 2026, accessed October 31, 2026
- SS Innovations, Response to FDA request for additional information on the SSi Mantra 510(k), October 13, 2026, accessed October 31, 2026
- Distalmotion, Distalmotion raises $150 million, November 18, 2025, accessed November 1, 2026
- CMR Surgical, Stryker and CMR Surgical announce strategic alliance, October 12, 2026, accessed November 2, 2026
- Distalmotion, Distalmotion accelerates US commercial momentum in ASCs, May 21, 2026, accessed November 2, 2026
- Distalmotion, Homepage, accessed November 2, 2026
- MedTech Dive, Surgeries are moving to ASCs. Distalmotion wants its robot to drive the shift., accessed November 2, 2026

